

Han W Tun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6790194/publications.pdf>

Version: 2024-02-01

85
papers

1,363
citations

430874

18
h-index

377865

34
g-index

85
all docs

85
docs citations

85
times ranked

2118
citing authors

#	ARTICLE	IF	CITATIONS
1	Pathway analysis of primary central nervous system lymphoma. Blood, 2008, 111, 3200-3210.	1.4	156
2	Neuronal Pentraxin 2 Supports Clear Cell Renal Cell Carcinoma by Activating the AMPA-Selective Glutamate Receptor-4. Cancer Research, 2014, 74, 4796-4810.	0.9	155
3	Pathway Signature and Cellular Differentiation in Clear Cell Renal Cell Carcinoma. PLoS ONE, 2010, 5, e10696.	2.5	146
4	The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. Blood, 2015, 126, 328-335.	1.4	92
5	Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. Blood, 2018, 132, 2240-2248.	1.4	90
6	Pomalidomide Shows Significant Therapeutic Activity against CNS Lymphoma with a Major Impact on the Tumor Microenvironment in Murine Models. PLoS ONE, 2013, 8, e71754.	2.5	77
7	Introduction of novel agents in the treatment of primary CNS lymphoma. Neuro-Oncology, 2019, 21, 306-313.	1.2	63
8	Defining the human kidney N-glycome in normal and cancer tissues using MALDI imaging mass spectrometry. Journal of Mass Spectrometry, 2020, 55, e4490.	1.6	40
9	Accelerated bottom-up drug design platform enables the discovery of novel stearyl-CoA desaturase 1 inhibitors for cancer therapy. Oncotarget, 2018, 9, 3-20.	1.8	35
10	Excellent Outcome of Immunomodulation or Bruton's Tyrosine Kinase Inhibition in Highly Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. Rare Tumors, 2015, 7, 164-166.	0.6	34
11	A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL).. Blood, 2007, 110, 121-121.	1.4	31
12	Persistent Disparities Among Patients With T-Cell Non-Hodgkin Lymphomas and B-Cell Diffuse Large Cell Lymphomas Over 40 Years: A SEER Database Review. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 578-585.	0.4	27
13	Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?. Radiotherapy and Oncology, 2022, 166, 171-179.	0.6	27
14	Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis. Biology of Blood and Marrow Transplantation, 2020, 26, 76-82.	2.0	26
15	Immune checkpoint inhibition by anti-PDCD1 (anti-PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model. British Journal of Haematology, 2018, 183, 674-678.	2.5	22
16	Pomalidomide Alters Pancreatic Macrophage Populations to Generate an Immune-Responsive Environment at Precancerous and Cancerous Lesions. Cancer Research, 2019, 79, 1535-1548.	0.9	22
17	An integrated approach to the discovery of potent agelastatin A analogues for brain tumors: chemical synthesis and biological, physicochemical and CNS pharmacokinetic analyses. MedChemComm, 2013, 4, 1093.	3.4	19
18	Successful Antimicrobial Treatment of Phlegmonous Gastritis: A Case Report and Literature Review. Case Reports in Hematology, 2018, 2018, 1-5.	0.4	19

#	ARTICLE	IF	CITATIONS
19	Functional genomics identifies novel genes essential for clear cell renal cell carcinoma tumor cell proliferation and migration. <i>Oncotarget</i> , 2014, 5, 5320-5334.	1.8	18
20	Pharmacokinetics of Agelastatin A in the central nervous system. <i>MedChemComm</i> , 2012, 3, 233-237.	3.4	15
21	Primary histiocytic sarcoma of the central nervous system: a case report with platelet derived growth factor receptor mutation and PD-L1/PD-L2 expression and literature review. <i>Radiation Oncology</i> , 2018, 13, 167.	2.7	14
22	Osteopontin is a multi-faceted pro-tumorigenic driver for central nervous system lymphoma. <i>Oncotarget</i> , 2016, 7, 32156-32171.	1.8	14
23	Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Waldenström Macroglobulinemia: A Systematic Review and Meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e694-e711.	0.4	13
24	Selective central nervous system tropism of primary central nervous system lymphoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2010, 3, 763-7.	0.5	13
25	CD47 and Osteopontin Expression in Diffuse Large B-cell Lymphoma With Nodal and Intravascular Involvement. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 597-601.	0.4	11
26	Molecular analysis of intravascular large B-cell lymphoma with neoangiogenesis. <i>British Journal of Haematology</i> , 2011, 152, 234-236.	2.5	10
27	Outcomes of Hepatosplenic T-Cell Lymphoma: The Mayo Clinic Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 106-112.e1.	0.4	9
28	A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas. <i>Blood</i> , 2019, 134, 810-810.	1.4	9
29	Primary central nervous system B cell lymphoma with features intermediate between diffuse large B cell lymphoma and Burkitt lymphoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2012, 5, 72-6.	0.5	9
30	Pharmacokinetics of bendamustine in the central nervous system: chemoinformatic screening followed by validation in a murine model. <i>MedChemComm</i> , 2012, 3, 1526.	3.4	8
31	Molecular and phenotypic characterization of an early T-cell precursor acute lymphoblastic lymphoma harboring PICALM-MLLT10 fusion with aberrant expression of B-cell antigens. <i>Cancer Genetics</i> , 2020, 240, 40-44.	0.4	8
32	Safety, Pharmacokinetics and Activity of CA-4948, an IRAK4 Inhibitor, for Treatment of Patients with Relapsed or Refractory Hematologic Malignancies: Results from the Phase 1 Study. <i>Blood</i> , 2020, 136, 44-45.	1.4	8
33	Differential gene expression of central nervous system lymphoma. <i>Blood</i> , 2009, 113, 267-268.	1.4	7
34	Hairy Cell Lymphoma: A Potentially Under-Recognized Entity. <i>Rare Tumors</i> , 2017, 9, 1-3.	0.6	7
35	Mantle cell lymphoma with a novel t(11;12)(q13;p11.2): a proposed alternative mechanism of CCND1 up-regulation. <i>Human Pathology</i> , 2017, 64, 207-212.	2.0	6
36	Comparable Efficacy of Reduced Dose Radiation Therapy for the Treatment of Early Stage Gastric Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue. <i>Advances in Radiation Oncology</i> , 2021, 6, 100714.	1.2	6

#	ARTICLE	IF	CITATIONS
37	Preclinical Evaluation of Ibrutinib for Central Nervous System Lymphoma. <i>Blood</i> , 2016, 128, 4170-4170.	1.4	6
38	C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, 14, 141-146.	0.9	5
39	Primary Cauda Equina Lymphoma Treated with CNS-Centric Approach: A Case Report and Literature Review. <i>Journal of Blood Medicine</i> , 2021, Volume 12, 645-652.	1.7	5
40	Clinical Characteristics and Survival Outcomes of Primary Effusion Lymphoma: A National Cancer Database Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e485-e494.	0.4	5
41	A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome. <i>Blood Advances</i> , 2022, 6, 4241-4250.	5.2	5
42	Autologous Stem Cell Transplantation in Central Nervous System Lymphoma: A Multicenter Retrospective Series and a Review of the Literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e273-e280.	0.4	4
43	BRAF p.V600E associated poly-neoplastic syndrome. <i>Rare Tumors</i> , 2021, 13, 203636132110129.	0.6	4
44	Long-Term Outcome of Patients with Low-Grade Follicular Lymphoma Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience. <i>Blood</i> , 2019, 134, 2809-2809.	1.4	4
45	Phase 1 Dose-Finding Study Investigating CA-4948, an IRAK4 Kinase Inhibitor, in Patients with R/R NHL: Report of Initial Efficacy and Updated Safety Information. <i>Blood</i> , 2019, 134, 5327-5327.	1.4	4
46	Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models. <i>Oncotarget</i> , 2018, 9, 28155-28164.	1.8	4
47	Macrophage Activation Led Acute Heart Failure Managed Successfully with Immunosuppression. <i>Journal of Blood Medicine</i> , 2021, Volume 12, 1037-1043.	1.7	4
48	Real World Long-term Follow-up Experience with Yttrium-90 Ibritumomab tiuxetan in Previously Untreated Patients with Low-Grade Follicular Lymphoma and Marginal Zone Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 618-625.	0.4	4
49	T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Presenting as a Primary Central Nervous System Lymphoma. <i>Rare Tumors</i> , 2015, 7, 160-162.	0.6	3
50	Impact of hypoalbuminemia on the prognosis of relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel. <i>European Journal of Haematology</i> , 2021, 107, 48-53.	2.2	3
51	The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672). <i>Blood</i> , 2019, 134, 1591-1591.	1.4	3
52	Long-Term Survival with Ibrutinib Therapy in Elderly Patients with Newly Diagnosed Primary Central Nervous System Lymphoma. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2022, Volume 12, 23-29.	2.7	3
53	Open-label, dose-escalation, and expansion trial of CA-4948 in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7575-7575.	1.6	3
54	Allogeneic hematopoietic cell transplant for relapsed-refractory, marginal zone lymphoma: a single-center experience. <i>Leukemia and Lymphoma</i> , 2018, 59, 2727-2730.	1.3	2

#	ARTICLE	IF	CITATIONS
55	Pharmacokinetics-based clinical management of acquired von Willebrand syndrome: a case report. <i>Journal of Blood Medicine</i> , 2018, Volume 9, 9-13.	1.7	2
56	Impact of Cell of Origin on Outcomes After Autologous Hematopoietic Cell Transplant in Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e89-e95.	0.4	2
57	Long-Term Outcome of Patients with Marginal Zone Non-Hodgkin Lymphoma (MZL) Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience. <i>Blood</i> , 2019, 134, 1544-1544.	1.4	2
58	Cost Analysis of R-CHOP <i>versus</i> Dose-Adjusted R-EPOCH in Treatment of Diffuse Large B-Cell Lymphoma with High-Risk Features. <i>Clinical Hematology International</i> , 2020, 2, 117.	1.7	2
59	Impact of Novel Agents on the Outcomes of Patients with Classic Hodgkin Lymphoma That Relapsed after Autologous Stem Cell Transplant. <i>Blood</i> , 2021, 138, 1373-1373.	1.4	2
60	Neuropsychiatric Manifestations of Lymphoma-Associated Cerebral Glucose Hypometabolism Can Be Reversed by Intensive Glucose Supplementation. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2022, Volume 12, 17-21.	2.7	2
61	Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e815-e825.	0.4	2
62	Intravascular Large B Cell Lymphoma with CNS Involvement Successfully Treated with High-Dose Methotrexate and High-Dose Ara-C Based CNS-Directed Chemoimmunotherapy Alternating with Anthracycline Based Chemoimmunotherapy. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 0, Volume 12, 47-54.	2.7	2
63	A case of exuberant cutaneous lymphomagenesis in the setting of chronic patch mycosis fungoides. <i>JAAD Case Reports</i> , 2015, 1, 46-48.	0.8	1
64	Obinutuzumab as bridging therapy for successful manufacturing of axicabtagene ciloleucel for transformed follicular lymphoma with circulating cells. <i>American Journal of Hematology</i> , 2019, 94, E245-E247.	4.1	1
65	A Virtual Screening Platform Identifies Chloroethylagelastatin A as a Potential Ribosomal Inhibitor. <i>Biomolecules</i> , 2020, 10, 1407.	4.0	1
66	Primary age-related EBV-associated effusion-based lymphoma successfully treated with rituximab and thoracentesis. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e03971.	0.5	1
67	Salvage therapies in transplant-eligible relapsed classic Hodgkin lymphoma, are novel regimens better?. <i>Journal of Clinical Oncology</i> , 2021, 39, 7530-7530.	1.6	1
68	Successful Non-Transplant Treatment of Double Hit Richter Transformation with Long-Term Remission. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2021, Volume 11, 67-72.	2.7	1
69	Phase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in Relapsed/Refractory Lymphoma Patients through Fixed-Dose Combination and Synthetic Lethality. <i>Blood</i> , 2018, 132, 5384-5384.	1.4	1
70	Baseline Hypoalbuminemia Does Not Appear to be an Adverse Prognostic Factor in Patients with Relapse/Refractory B-Cell Lymphomas Treated with Axicabtagene Ciloleucel (axi-cel). <i>Blood</i> , 2019, 134, 5343-5343.	1.4	1
71	Parsaclisib in Combination with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Preliminary Results of a Phase 1/1b Study. <i>Blood</i> , 2021, 138, 1415-1415.	1.4	1
72	A Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a Novel IRAK4 Inhibitor CA-4948 in Combination with Ibrutinib, in Patients with Relapsed or Refractory Hematologic Malignancies. <i>Blood</i> , 2020, 136, 49-50.	1.4	1

#	ARTICLE	IF	CITATIONS
73	Compounds, compositions, and methods of agelastatin alkaloids: patent evaluation of WO2015042239 (A1). Expert Opinion on Therapeutic Patents, 2017, 27, 113-119.	5.0	0
74	Follicular lymphoma associated paraneoplastic myositis. Clinical Case Reports (discontinued), 2020, 8, 2003-2006.	0.5	0
75	Diffuse large B-cell lymphoma with leukemic involvement.. Journal of Clinical Oncology, 2021, 39, e19552-e19552.	1.6	0
76	Primary HHV-8 (-) Effusion-Based Non-Germinal Center B Cell Diffuse Large B Cell Lymphoma Successfully Treated with Standard Anthracycline-Based Chemoimmunotherapy. Journal of Blood Medicine, 2021, Volume 12, 833-838.	1.7	0
77	Platelet Count Is a Sensitive Predictor of Bone Marrow Reserve and Autologous Peripheral Blood Progenitor Cell Mobilization.. Blood, 2005, 106, 5280-5280.	1.4	0
78	Novel Proteasome Inhibitors Induce Mitochondrial Destabilization and Activate Caspase Mediated Apoptosis In Preclinical Models Of Pediatric B-Cell Cancers. Blood, 2013, 122, 5140-5140.	1.4	0
79	Clinical Outcomes and Cost Analysis of Dose-Adjusted R-EPOCH Vs R-CHOP in Treatment of Diffuse Large B- Cell Lymphoma with High Risk Features. Blood, 2018, 132, 4790-4790.	1.4	0
80	Impact of Anti-CD19 CAR-T Axicabtagene Ciloleucel on Vaccine Titers of DTaP and MMR. Blood, 2019, 134, 5610-5610.	1.4	0
81	Utilization and Cost Effectiveness of First-Line Yttrium-90 Ibritumomab Tiuxetan in Low-Grade Follicular and Marginal Zone Lymphomas Compared to Standard of Care Bendamustine Plus Rituximab: A Real-World Experience. Blood, 2021, 138, 4020-4020.	1.4	0
82	Characteristics, Management and Outcomes of Patients with Intravascular Lymphoma: A Mayo Clinic Experience. Blood, 2021, 138, 1452-1452.	1.4	0
83	CD68+ Tumor Associated Macrophages Have Significant Impact on Therapeutic Outcome in Newly Diagnosed Multiple Myeloma (MM). Blood, 2020, 136, 4-5.	1.4	0
84	Impact of Cell of Origin (COO) on Long Term Outcomes Post Autologous Hematopoietic Cell Transplant in Patients with Relapsed/ Refractory Chemotherapy Sensitive De-Novo Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2020, 136, 42-43.	1.4	0
85	Combined modality therapy for early-stage Hodgkin lymphoma in the PET era: A real-world study.. Journal of Clinical Oncology, 2022, 40, e19532-e19532.	1.6	0